...INDICATION: Staphylococcus Cell culture studies suggest inhibiting adenosine kinase, DCK or SLC29A1 could help treat Staphylococcus...
...knockout of adenosine kinase, DCK or SLC29A1 decreased cell death compared with normal adenosine kinase, DCK...
...oral small molecule DCK inhibitor, in preclinical testing to treat hematologic malignancies. TARGET/MARKER/PATHWAY: Adenosine kinase; deoxycytidine kinase (DCK)...

...thinking about future products or variants for AML. For one, it plans to delete the DCK...
...College, New York, N.Y. Targets and Compounds CD123 - Interleukin-3 (IL-3) receptor α DCK - Deoxycytidine kinase...
...TCR - T cell receptor; TCRA - T cell receptor α chain; DCK - Deoxycytidine kinase...

...antigen receptor (CAR) and other T cell immunotherapies. Cells expressing a triple mutant of human DCK...
...model of melanoma receiving the imaging agent, human T cells engineered to express the mutant DCK...
...testing the mutant DCK-based PET imaging approach in clinical trials of T cell immunotherapies. DESCRIPTION: Deoxycytidine kinase (DCK)-based...

...gemcitabine's three primary resistance mechanisms. It enters cells independently of nucleoside transporters, does not require deoxycytidine kinase (DCK)...

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute lymphocytic leukemia (ALL) Deoxycytidine kinase (DCK) In...
...nucleotide salvage pathway. In human T cell ALL lines, the combination of dT plus a DCK...
...and toxicology. SciBX 7(13); doi:10.1038/scibx.2014.364 Published online April 3, 2014 Patent application filed for the DCK...

...Cancer Deoxycytidine kinase (DCK) Mouse and in vitro studies identified DCK inhibitors that could help treat cancer. DCK...
...chemotherapy resistance. High throughput screening, SAR studies and cell-based assays identified small molecules that inhibit DCK...
...nanomolar IC50 values. In a mouse xenograft model of human leukemia, the lead inhibitor decreased DCK...

..."CYC682 may be particularly active in tumors with a low ratio of cytidine deaminase to deoxycytidine kinase...